^
    Evidence Level:
    Sensitive: C3 – Early Trials

    [TMB-H + PD-L1 expression-Non Small Cell Lung Cancer-nivolumab + ipilimumab]

    Source:
    ESMO-IO 2022
    Test:

    FoundationOne® CDx, GuardantOMNI, TruSight Oncology 500 Assay

    Title:
    2MO - First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): clinical outcomes and biomarker analyses from CheckMate 592
    Published date:
    12/01/2022
    Excerpt:
    BL characteristics were generally similar between Part 1 (n = 60) and Part 2 (n = 170), and across tTMB and bTMB subgroups. At 12.5-mo minimum follow up, ORR in Part 1 was 30% and 39% in PD-L1 ≥1% (n = 30) and <1% (n = 28) subgroups, respectively. ORR by TMB (Parts 1 and 2 combined) is shown in the table....In CheckMate 592, high tTMB and bTMB were associated with better responses to 1L NIVO + IPI in pts with mNSCLC.
    Trial ID:
    CheckMate 592
    Evidence Level:
    Sensitive: C3 – Early Trials

    [TMB-H-Non Small Cell Lung Cancer-Immunotherapy]

    Source:
    ESMO 2020
    Test:

    TruSight Oncology 500 Assay

    Title:
    1037P - Tumour mutational burden and HLA diversity by TruSight oncology 500 (TSO500) next generation sequencing panel and clinical outcome in non-small cell lung cancer
    Published date:
    09/14/2020
    Excerpt:
    NSCLC patients with high TMB by TSO500, show higher RR to immunotherapy. HLA diversity score alone could not predict response, however combined high TMB and HLA diversity score show higher RR and DCR. Combined TMB, HLA diversity and PD-L1 can identify NSCLC patients likely to respond to or unlikely to benefit from IO. Hence TMB and HLA diversity score should be considered part of comprehensive genomic profiling.
    Evidence Level:
    Sensitive: C4 – Case Studies

    [BRAF V600E-Synovial Sarcoma-vemurafenib]

    Source:
    Oncotarget
    Test:

    TruSight Oncology 500 Assay

    Title:
    Intrathoracic synovial sarcoma with BRAF V600E mutation
    Published date:
    07/07/2023
    Excerpt:
    We report a case of 15-year-old boy with intrathoracic synovial sarcoma who relapsed after standard chemotherapy, surgery and radiotherapy. The molecular analysis of the tumour identified a BRAF V600E mutation…The patient underwent selective BRAF inhibitor Vemurafenib treatment achieving partial response (PR) with a progression free survival (PFS) ratio of 1.6 months and an overall survival of 19 months, alive in continuous PR.
    DOI:
    https://doi.org/10.18632/oncotarget.28475